STOCK TITAN

ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ASLAN Pharmaceuticals (NASDAQ: ASLN) will present a company update at the H.C. Wainwright Global Investment Conference from May 23 to 26, 2022. CEO Dr. Carl Firth will share insights on the company's innovative treatments targeting immunology. The presentation will be accessible starting May 24, 2022, at 7:00 AM ET for 90 days via the provided link and on ASLAN’s website. Additionally, ASLAN management is open to virtual one-on-one meetings during the conference. The company focuses on developing therapies for atopic dermatitis and autoimmune diseases.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif. and SINGAPORE, May 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a company update at the H.C. Wainwright Global Investment Conference. The conference will be held virtually and in-person from May 23 to 26, 2022. 

The presentation will be available from Tuesday, May 24, 2022, at 7:00am ET for 90 days at this link and in the Investors section of ASLAN’s website.

ASLAN management will also be available for virtual one-on-one meetings throughout the conference. Please contact your representative at H.C. Wainwright to request a meeting.

About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

Media and IR contacts

Emma Thompson
Spurwing Communications
Tel: +65 6206 7350
Email: ASLAN@spurwingcomms.com
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: +1 (617) 430-7577
Email: arr@lifesciadvisors.com

 


FAQ

What is ASLAN Pharmaceuticals presenting at the H.C. Wainwright Global Investment Conference?

ASLAN Pharmaceuticals will present a company update and insights on its innovative treatments during the H.C. Wainwright Global Investment Conference from May 23 to 26, 2022.

When can I access the ASLAN Pharmaceuticals presentation from the conference?

The ASLAN Pharmaceuticals presentation will be available starting May 24, 2022, at 7:00 AM ET for 90 days.

Who will present on behalf of ASLAN Pharmaceuticals at the conference?

Dr. Carl Firth, the CEO of ASLAN Pharmaceuticals, will present a company update at the H.C. Wainwright Global Investment Conference.

What is the focus of ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals focuses on developing immunology-based treatments, particularly for atopic dermatitis and autoimmune diseases.

ASLAN Pharmaceuticals Limited American Depositary Shares

NASDAQ:ASLN

ASLN Rankings

ASLN Latest News

ASLN Stock Data

1.70M
2.82M
0.14%
13.21%
1.35%
Biotechnology
Healthcare
Link
United States of America
Singapore